CN1146422C - 2-甲基-噻吩并-苯并二氮杂�制剂 - Google Patents

2-甲基-噻吩并-苯并二氮杂�制剂 Download PDF

Info

Publication number
CN1146422C
CN1146422C CNB998115355A CN99811535A CN1146422C CN 1146422 C CN1146422 C CN 1146422C CN B998115355 A CNB998115355 A CN B998115355A CN 99811535 A CN99811535 A CN 99811535A CN 1146422 C CN1146422 C CN 1146422C
Authority
CN
China
Prior art keywords
olanzapine
cholesterol
pva
embonate
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB998115355A
Other languages
English (en)
Chinese (zh)
Other versions
CN1320038A (zh
Inventor
Ca
C·A·邦尼尔
�ƶ�ɭ
T·H·菲尔古森
�������ɭ
B·A·亨德利克森
����ɣ��-����˹����˹
M·V·桑切兹－菲利克斯
D·E·图珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/163,769 external-priority patent/US6169084B1/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1320038A publication Critical patent/CN1320038A/zh
Application granted granted Critical
Publication of CN1146422C publication Critical patent/CN1146422C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB998115355A 1998-09-30 1999-03-24 2-甲基-噻吩并-苯并二氮杂�制剂 Expired - Lifetime CN1146422C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16376898A 1998-09-30 1998-09-30
US09/163769 1998-09-30
US09/163,769 US6169084B1 (en) 1997-09-30 1998-09-30 2-methyl-thieno-benzodiazepine formulation
US09/163768 1998-09-30

Publications (2)

Publication Number Publication Date
CN1320038A CN1320038A (zh) 2001-10-31
CN1146422C true CN1146422C (zh) 2004-04-21

Family

ID=26859927

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998115355A Expired - Lifetime CN1146422C (zh) 1998-09-30 1999-03-24 2-甲基-噻吩并-苯并二氮杂�制剂

Country Status (28)

Country Link
EP (1) EP1119359B1 (enExample)
JP (1) JP4551988B2 (enExample)
CN (1) CN1146422C (enExample)
AT (2) ATE267602T1 (enExample)
AU (1) AU759751B2 (enExample)
BR (1) BR9914156A (enExample)
CA (1) CA2344873A1 (enExample)
CZ (1) CZ302367B6 (enExample)
DE (2) DE69935873T2 (enExample)
DK (2) DK1119359T3 (enExample)
EA (1) EA002580B1 (enExample)
ES (2) ES2285294T3 (enExample)
GE (1) GEP20094818B (enExample)
HK (1) HK1041199B (enExample)
HR (1) HRP20010238B1 (enExample)
HU (1) HU227400B1 (enExample)
ID (1) ID29574A (enExample)
IL (2) IL141766A0 (enExample)
MY (1) MY126476A (enExample)
NO (1) NO328243B1 (enExample)
NZ (1) NZ510208A (enExample)
PL (1) PL196821B1 (enExample)
PT (2) PT1119359E (enExample)
SK (1) SK285944B6 (enExample)
TR (1) TR200100885T2 (enExample)
TW (1) TW577890B (enExample)
UA (1) UA66872C2 (enExample)
WO (1) WO2000018408A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102665401A (zh) * 2009-11-16 2012-09-12 益普生制药股份有限公司 黑皮质素受体配体的药物组合物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047933A1 (en) * 1999-12-28 2001-07-05 Cipla Limited New polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
DE05783995T1 (de) * 2004-07-14 2007-10-11 Shasun Chemicals and Drugs Ltd., Chennai Verbessertes verfahren zur herstellung von form i aus olanzapin
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
EP1838716B1 (en) * 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapine pamoate dihydrate
CZ2006697A3 (cs) * 2006-11-07 2008-05-21 Zentiva, A. S. Kompozice depotních olanzapinových injekcních systému
FR2927965B1 (fr) * 2008-02-22 2010-06-04 Valeo Materiaux De Friction Sa Procede de fabrication d'un materiau de friction et notamment d'une couronne de friction d'embrayage.
WO2011091142A2 (en) * 2010-01-20 2011-07-28 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of olanzapine pamoate
WO2012053654A1 (en) 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
US9604995B2 (en) 2013-02-13 2017-03-28 Neuland Laboratories Limited Process for the preparation of olanzapine pamoate
CN105044231B (zh) * 2015-06-27 2022-09-13 万特制药(海南)有限公司 一种分离测定奥氮平双羟萘酸盐一水合物有关物质的方法
JP2020511483A (ja) * 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA933134B (en) * 1992-05-08 1993-11-30 Akzo Nv Depot preparation
KR100333115B1 (ko) * 1992-11-17 2002-12-02 미츠비시 파마 코포레이션 항정신병약함유서방성마이크로스피어및이의제조방법
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
TR199900639T2 (xx) * 1996-09-23 1999-06-21 Eli Lilly And Company Olanzapin dihidrat D.
US6169084B1 (en) * 1997-09-30 2001-01-02 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102665401A (zh) * 2009-11-16 2012-09-12 益普生制药股份有限公司 黑皮质素受体配体的药物组合物

Also Published As

Publication number Publication date
ID29574A (id) 2001-09-06
DK1468689T3 (da) 2007-08-13
CN1320038A (zh) 2001-10-31
EA002580B1 (ru) 2002-06-27
PL196821B1 (pl) 2008-02-29
HUP0103636A3 (en) 2003-05-28
EP1119359A1 (en) 2001-08-01
HRP20010238A2 (en) 2002-04-30
PL346981A1 (en) 2002-03-11
IL141766A (en) 2006-12-31
NO20011583D0 (no) 2001-03-28
TW577890B (en) 2004-03-01
NO328243B1 (no) 2010-01-11
GEP20094818B (en) 2009-11-10
DE69935873T2 (de) 2008-01-10
HK1041199B (en) 2005-03-18
EP1119359A4 (en) 2001-12-19
JP2002525330A (ja) 2002-08-13
IL141766A0 (en) 2002-03-10
PT1119359E (pt) 2004-08-31
WO2000018408A1 (en) 2000-04-06
ATE267602T1 (de) 2004-06-15
HRP20010238B1 (en) 2006-05-31
AU3362799A (en) 2000-04-17
EA200100406A1 (ru) 2001-10-22
MY126476A (en) 2006-10-31
BR9914156A (pt) 2001-06-26
CZ302367B6 (cs) 2011-04-13
SK4162001A3 (en) 2002-03-05
CZ20011149A3 (cs) 2002-01-16
HU227400B1 (en) 2011-05-30
PT1468689E (pt) 2007-07-09
NO20011583L (no) 2001-03-28
TR200100885T2 (tr) 2001-08-21
CA2344873A1 (en) 2000-04-06
DK1119359T3 (da) 2004-08-16
DE69935873D1 (de) 2007-05-31
ES2285294T3 (es) 2007-11-16
AU759751B2 (en) 2003-05-01
HUP0103636A2 (hu) 2002-01-28
DE69917663D1 (de) 2004-07-01
DE69917663T2 (de) 2005-05-25
UA66872C2 (uk) 2004-06-15
JP4551988B2 (ja) 2010-09-29
ES2221376T3 (es) 2004-12-16
NZ510208A (en) 2003-04-29
HK1041199A1 (en) 2002-07-05
SK285944B6 (sk) 2007-11-02
EP1119359B1 (en) 2004-05-26
ATE359793T1 (de) 2007-05-15

Similar Documents

Publication Publication Date Title
CN1239158C (zh) 2－甲基－噻吩并－苯并二氮杂䓬制剂
CN1146422C (zh) 2-甲基-噻吩并-苯并二氮杂�制剂
CN1020093C (zh) 1-苯基-3-萘氧基丙胺的制备方法
CN1048490C (zh) 环状衍生物、含该衍生物的药物组合物及应用
CN1089583C (zh) 霉酚酸2－(4－吗啉代)乙酯高剂量口服悬浮剂
CN1312800A (zh) 治疗用的联芳基衍生物
CN1019113B (zh) 3-芳氢基-3-取代的丙胺的制法
CN1268133A (zh) 含有稠合环取代基的作为nos抑制剂的2－氨基吡啶
CN1234738A (zh) 奥氮平二水合物d
CN1509174A (zh) 5,8,14－三氮杂四环[10.3.1.02，11.04，9]－十六－2(11),3,5,7,9,－五烯的酒石酸盐
CN1202107A (zh) 选择性β3肾上腺素兴奋剂
CN1030252C (zh) 四氢苯并咪唑衍生物的制备方法
CN1210521A (zh) 异喹啉衍生物及医药
CN1946406A (zh) 治疗呼吸道疾病的苯并噁嗪
CN1067073C (zh) 非环式核苷衍生物
CN1053062A (zh) 新的维生素e衍生物及其制备方法
CN1083475A (zh) 乙酸衍生物
CN1159303C (zh) 单环β-内酰胺类抗生素衍生物的中间体的制备方法
CN1084169A (zh) 新的苯基吡咯衍生物及其制备方法和用途
CN1217719A (zh) 新型苯并呋喃酮衍生物及其制备方法
CN87100978A (zh) 新的二氢苯并呋喃—和苯并二氢吡喃—羧酰胺衍生物及其制备方法以及作为精神抑制药的应用
CN101058558A (zh) 具有醛糖还原酶抑制活性的4－氧代－1(4h)－喹啉羧酸类化合物、组合物及其制备方法
CN1090282A (zh) 苯稠合羟基取代的环烷基和杂环化合物的磺酰胺衍生物
CN1028527C (zh) 香豆素衍生物的制备方法
CN1145361A (zh) 新的喹唑啉化合物和含所述化合物作为活性成分的抗肿瘤剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20040421